Rodger D. MacArthur, MD

March 10, 2014

The good: this premier HIV conference offers a banquet of exceptional material. The bad: the expense and the grind of covering a meeting this rich-and lengthy.

March 10, 2014

Two studies demonstrate that raltegravir is an extremely well-tolerated and potent component of a combination antiretroviral regimen.

March 07, 2014

“Super-spreaders” continue to play a major role in various epidemics, including tuberculosis and HIV infection.

March 05, 2014

It is quite likely that we have entered a new era of treatment for individuals either mono-infected with HCV or co-infected with HCV/HIV. Details here.

March 04, 2014

The START trial is likely to provide a definitive answer to one of the most important clinical questions in HIV management: when is the optimal time to start antiretroviral therapy.

February 25, 2014

Stark defunding for AIDS research may lead to increased pharmaceutical influence, less population diversity in research, and dwindling new HIV-specific advances.

November 09, 2013

First of all, it is important to know what exactly is meant by “the best.”

October 03, 2013

HIV infection had ravaged Amber's immune system, but not her spirit. Here, her story told by the physician who continues to walk with her.

August 23, 2013

Coinfection with HIV and HCV presents a problem: many of the drugs used routinely to treat HIV have adverse interactions with the newer, and older, treatments for HCV.

June 19, 2013

Women tend to be excluded from pharmaceutical company-sponsored trials of antiretroviral medications.